MedPath

SYNDEVRX, INC.

SYNDEVRX, INC. logo
🇺🇸United States
Ownership
Private
Established
2007-01-01
Employees
1
Market Cap
-
Website
http://www.syndevrx.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Phase 1
Recruiting
Conditions
HR+/HER2-negative Breast Cancer
Metastatic Breast Cancer
Interventions
First Posted Date
2022-07-13
Last Posted Date
2025-05-29
Lead Sponsor
SynDevRx, Inc.
Target Recruit Count
52
Registration Number
NCT05455619
Locations
🇺🇸

SHARP Healthcare, San Diego, California, United States

🇺🇸

Hope and Healing Cancer Services, Hinsdale, Illinois, United States

🇺🇸

Trinity Health, Ypsilanti, Michigan, United States

and more 7 locations

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Neoplasm
Advanced Malignancy
Metastasis
Interventions
First Posted Date
2016-04-19
Last Posted Date
2020-01-27
Lead Sponsor
SynDevRx, Inc.
Target Recruit Count
32
Registration Number
NCT02743637
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.